Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Johns Hopkins University
With
National Institute of Neurological Disorders and Stroke (NINDS)
secondary objectives:
1. To assess the change from baseline to 20 weeks on biomarkers of oxidative stress (8OHdG and 8OHrG) and DNA repair mechanisms (OGG1) in pre-manifest participants treated with 600, 1200 or 2400 mg per day of CoQ10.
2. To assess the dose-response relationship between CoQ10 at dosages of 600, 1200 or 2400 mg per day and 8OHdG/8OHrG and OGG1.
3. To assess the serum levels of CoQ10 at 600, 1200 or 2400 mg in pre-manifest participants and their relationship to 8OHdG/8OHrG and OGG1.
4. To assess the feasibility of implementing a preventive therapeutic trial in a pre-manifest population.
5. To assess the utility and stability of clinical measures of HD, social relations, behavior and employment in a pre-manifest sample enrolled in a treatment trial.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants will be positive for the CAGn expansion in the Huntingtin gene (\>36 repeats) and be pre-manifest by virtue of scoring 3 or less on diagnostic confidence level (Question 17 of the UHDRS)
Participants will have received genetic testing prior to enrollment through a standard pre-manifest testing protocol.
18 years of age or older.
Concomitant medications are permitted with the exception of CoQ10, creatine \> 5g/day and warfarin.
You may not be if
History of intolerability to CoQ10.
CoQ10 use within 60 days prior to randomization.
Unstable medical or psychiatric illness;
Substance abuse within one year of the baseline visit.
Pregnancy, breastfeeding or lack of reliable contraception in women of childbearing age.
Subjects with known allergy to FD\&C #6 yellow food coloring.